{
  "label": "clinical_signal_03_ep_010",
  "artifact_type": "signal_episode",
  "artifact_id": "sha256:cab0ed69f1fa476255e68bf8c3e4cc9b8de1271b593421292819215fb07dd0fd",
  "input_ids": [
    "sha256:b4ba5337b06c8de68ac3315db1a4f6980c5bd48efd529c3914f30297d6afd329",
    "sha256:161174e8025b5c956602ccc4e17b4e677c58230b1b64641f357c400c448b8151"
  ],
  "prompt_id": null,
  "model_config": null,
  "created_at": "2026-02-17T11:54:37.764422",
  "content": "## 2024-05-06 Daily Operations Summary\n\n### Enrollment\n- Total Randomized: 184\n- Active: 182\n- Screen Failures Cumulative: 20\n- Withdrawals Cumulative: 2\n\n#### Sites\n- Site 01 Enrolled: 18\n- Site 01 Active: 18\n- Site 01 Statin Concomitant: 5\n- Site 02 Enrolled: 14\n- Site 02 Active: 14\n- Site 02 Statin Concomitant: 3\n- Site 03 Enrolled: 17\n- Site 03 Active: 17\n- Site 03 Statin Concomitant: 4\n- Site 04 Enrolled: 12\n- Site 04 Active: 12\n- Site 04 Statin Concomitant: 3\n- Site 05 Enrolled: 15\n- Site 05 Active: 15\n- Site 05 Statin Concomitant: 5\n- Site 06 Enrolled: 11\n- Site 06 Active: 11\n- Site 06 Statin Concomitant: 3\n- Site 07 Enrolled: 20\n- Site 07 Active: 20\n- Site 07 Statin Concomitant: 5\n- Site 08 Enrolled: 14\n- Site 08 Active: 14\n- Site 08 Statin Concomitant: 3\n- Site 09 Enrolled: 15\n- Site 09 Active: 15\n- Site 09 Statin Concomitant: 5\n- Site 10 Enrolled: 12\n- Site 10 Active: 12\n- Site 10 Statin Concomitant: 3\n- Site 11 Enrolled: 17\n- Site 11 Active: 17\n- Site 11 Statin Concomitant: 5\n- Site 12 Enrolled: 14\n- Site 12 Active: 14\n- Site 12 Statin Concomitant: 3\n\n### Lab Panels\n#### Statin Subgroup\n- N: 54\n- ALT Mean (U/L): 37.2\n- ALT Median (U/L): 35.2\n- AST Mean (U/L): 32.1\n- AST Median (U/L): 30.9\n- Bilirubin Mean (mg/dL): 0.68\n- Bilirubin Median (mg/dL): 0.65\n- ALP Mean (U/L): 65.1\n- ALP Median (U/L): 62.3\n- Creatinine Mean (mg/dL): 1.09\n- Creatinine Median (mg/dL): 0.88\n- BUN Mean (mg/dL): 17.8\n- BUN Median (mg/dL): 16.4\n- WBC Mean (k): 6.3\n- WBC Median (k): 6.7\n- Platelets Mean (k): 245\n- Platelets Median (k): 228\n\n#### Non-Statin Subgroup\n- N: 132\n- ALT Mean (U/L): 23.2\n- ALT Median (U/L): 22.4\n- AST Mean (U/L): 27.8\n- AST Median (U/L): 25.9\n- Bilirubin Mean (mg/dL): 0.4\n- Bilirubin Median (mg/dL): 0.39\n- ALP Mean (U/L): 59.6\n- ALP Median (U/L): 48.6\n- Creatinine Mean (mg/dL): 0.81\n- Creatinine Median (mg/dL): 0.98\n- BUN Mean (mg/dL): 13.4\n- BUN Median (mg/dL): 12.1\n- WBC Mean (k): 8.4\n- WBC Median (k): 7.1\n- Platelets Mean (k): 261\n- Platelets Median (k): 236\n\n### Adverse Events\n- AE ID: AE-0029, Description: nasopharyngitis, Grade: 1, Relatedness: not related, Resolved: true, Subject Group: statin\n- AE ID: AE-0030, Description: dizziness, Grade: 1, Relatedness: possibly related, Resolved: true, Subject Group: non_statin\n- AE ID: AE-0031, Description: upper respiratory infection, Grade: 1, Relatedness: not related, Resolved: true, Subject Group: statin\n- AE ID: AE-0032, Description: transaminase measurement out of range, Grade: 1, Relatedness: possibly related, Resolved: true, Subject Group: statin\n\n### Concomitant Meds\n- Statin Count: 53\n- ACE Inhibitor Count: 30\n- Metformin Count: 24\n- PPI Count: 17\n- NSAID Count: 13\n- Other Count: 35\n\n### Protocol Deviations\n- PD ID: PD-024, Description: Incorrect lab panel order, repeated, Severity: minor, Site: site_07\n\n### Investigator Notes\n- Training log updated for new study coordinator\n- Subject retention rate within protocol targets\n- Statin subgroup lab review: ALT mean 42 U/L, within 1.5x ULN; monitoring per protocol\n\n### Events\n- EDC system maintenance window: 2h downtime Saturday 02:00 UTC\n- IP resupply shipped to Sites 11, 12\n- Site 12 monitoring visit completed, 4 findings\n\n### Notes\n- Week 10: Statin subgroup hepatic panel shows ALT values at upper range. Non-statin subgroup stable. Routine operations continue.",
  "metadata": {
    "episode_id": "clinical_signal_03_ep_010",
    "scope_id": "clinical_signal_03",
    "timestamp": "2024-05-06T10:00:00",
    "phase": "early_signal",
    "signal_density": "low",
    "episode_type": "signal",
    "layer_name": "signal_episodes",
    "layer_level": 2,
    "build_fingerprint": {
      "scheme": "synix:build:v1",
      "digest": "724335e48952198659b608a79f591f6985cc457d1b0726c271a193e4d218a284",
      "components": {
        "transform": "f5403588af46952374060f29447e5a7639e5b66fc9aef1799b08473882c4bcbc",
        "inputs": "a94b84fbaca9bd62"
      }
    },
    "transform_fingerprint": {
      "scheme": "synix:transform:v2",
      "digest": "f5403588af46952374060f29447e5a7639e5b66fc9aef1799b08473882c4bcbc",
      "components": {
        "transform_id": "cb4ddfa83a38701b",
        "source": "42e76241d396a578",
        "model": "1e2ccf75e96d7ee7"
      }
    }
  }
}